Projects per year
TIGIT is an inhibitory receptor expressed on lymphocytes and can inhibit T cells by preventing CD226 co-stimulation through interactions in cis or through competition of shared ligands. Whether TIGIT directly delivers cell-intrinsic inhibitory signals in T cells remains unclear. Here we show, by analysing lymphocytes from matched human tumour and peripheral blood samples, that TIGIT and CD226 co-expression is rare on tumour-infiltrating lymphocytes. Using super-resolution microscopy and other techniques, we demonstrate that ligation with CD155 causes TIGIT to reorganise into dense nanoclusters, which coalesce with T cell receptor (TCR)-rich clusters at immune synapses. Functionally, this reduces cytokine secretion in a manner dependent on TIGIT's intracellular ITT-like signalling motif. Thus, we provide evidence that TIGIT directly inhibits lymphocyte activation, acting independently of CD226, requiring intracellular signalling that is proximal to the TCR. Within the subset of tumours where TIGIT-expressing cells do not commonly co-express CD226, this will likely be the dominant mechanism of action.
- Lymphocyte Activation
- Lymphocytes, Tumor-Infiltrating
- Receptors, Immunologic/genetics
- Signal Transduction
Research Beacons, Institutes and Platforms
- Lydia Becker Institute
FingerprintDive into the research topics of 'TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation'. Together they form a unique fingerprint.
1/09/16 → 30/09/22